Tenecteplase for Acute Ischemic Stroke: From Molecular Bioengineering to Phase III Pivotal Trials

Article information

J Stroke. 2026;28(3):357-371
Publication date (electronic) : 2026 September 30
doi : https://doi.org/10.5853/jos.2026.03412
1Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
2Department of Radiology, Yonsei University College of Medicine, Seoul, Korea
3Department of Neurology, Ajou University School of Medicine, Ajou University Medical Center, Suwon, Korea
Correspondence: Jin Soo Lee Department of Neurology, Ajou University School of Medicine, Ajou University Medical Center, 164 World cup-ro, Yeongtong-gu, Suwon 16499, Korea Tel: +82-31-219-5175 E-mail: jinsoo22@gmail.com
Received 2026 May 28; Revised 2026 August 12; Accepted 2026 August 31.

Abstract

Intravenous thrombolysis with alteplase is a primary reperfusion therapy for acute ischemic stroke, yet its clinical utility is constrained by a short half-life, continuous infusion requirements, and susceptibility to plasminogen activator inhibitor-1. Tenecteplase, a bioengineered variant of alteplase, was developed to address these limitations through a prolonged half-life, increased fibrin specificity, and enhanced resistance to plasminogen activator inhibitor-1. These structural modifications enable single-bolus administration and reduce systemic fibrinolytic disturbance. In this review, we examine how the targeted molecular modifications of tenecteplase shaped its stepwise translational development in acute ischemic stroke. We first detail the limitations of alteplase, which motivated the transition to alternative agents, the molecular rationale for tenecteplase, and its preclinical evidence. Furthermore, we synthesize the phase II dose-finding trials that established 0.25 mg/kg as providing the optimal efficacy and safety balance, distinguishing it from the excess intracranial hemorrhage observed with the 0.4 mg/kg dose. Finally, we review the pivotal phase III trials across diverse populations demonstrating that tenecteplase 0.25 mg/kg is non-inferior to alteplase and represents a practical, evidence-based alternative, particularly where single-bolus administration may facilitate workflow or transfer for endovascular thrombectomy. Viewed through this molecular-to-clinical framework, the development of tenecteplase illustrates how targeted protein engineering can translate into pharmacological, operational, and clinical advantages in stroke reperfusion therapy.

Introduction

Intravenous thrombolysis remains a cornerstone of reperfusion therapy in acute ischemic stroke, with alteplase serving as the longstanding standard [1,2]. Following its initial approval for acute myocardial infarction (AMI) in 1987, alteplase was approved for acute ischemic stroke in the United States in 1996 and subsequently in Europe, establishing it as the foundational agent for modern intravenous reperfusion therapy [3-6].

Despite its established role, alteplase has several pharmacologic and practical limitations that constrain its optimal use in time-critical emergency settings. These include a short plasma half-life, dependence on continuous infusion, vulnerability to plasminogen activator inhibitor-1 (PAI-1), and relatively modest efficacy in early recanalization of large-vessel occlusion [7-11]. These limitations have stimulated interest in alternative thrombolytic agents with greater fibrin selectivity, more durable pharmacologic activity, and simpler administration [12,13].

Tenecteplase, as a bioengineered variant of alteplase, was developed to address these constraints [14]. Its prolonged half-life, increased fibrin specificity, and enhanced resistance to PAI-1 enable single-bolus administration and reduce systemic fibrinolytic disturbance. Over the past decade, tenecteplase has followed a rigorous translational pathway, from molecular engineering and preclinical validation to dose-finding studies and large-scale randomized trials, evolving into one of the most actively studied thrombolytics in modern stroke care [15-17].

This review examines how the targeted molecular modifications of tenecteplase shaped its translational development in acute ischemic stroke. We trace how this molecular engineering informed preclinical and pharmacological development, stroke-specific dose selection, and the design and interpretation of pivotal clinical trials.

Practical limitations of alteplase in stroke care

In acute ischemic stroke, alteplase is generally administered as a front-loaded regimen of 0.9 mg/kg, with 10% given as a bolus and the remainder infused over 1 hour. Although alteplase remains an established standard for intravenous thrombolysis in acute ischemic stroke, its infusion-based administration introduces practical challenges in real-world stroke care. Because its therapeutic effect depends on uninterrupted delivery after the initial bolus, delays between bolus and infusion are clinically relevant and may reduce effective drug exposure. In a single-center retrospective study including 229 patients, the mean bolus-to-infusion delay was 9±7 minutes [11]. Pharmacologic modeling suggests that such delays may allow substantial declines in circulating drug levels before steady-state exposure is achieved [18]. In addition, compared with tenecteplase, alteplase is less convenient to administer, as its initial bolus is given over 1 minute rather than 5–10 seconds [19]. These issues are particularly relevant in patients undergoing bridging therapy before endovascular thrombectomy. Consistent with these concerns, routine clinical practice data from a 10-hospital network showed that tenecteplase was associated with shorter door-to-needle and door-in-door-out times than alteplase, supporting the practical relevance of avoiding infusion-related workflow constraints [20].

In the setting of endovascular thrombectomy-eligible stroke, the practical limitations of alteplase may be particularly relevant. In the EXTEND-IA TNK (Extending the time for Thrombolysis in Emergency Neurological Deficits-Intra-Arterial using intravenous Tenecteplase) Part 1 trial, tenecteplase achieved approximately twofold higher early recanalization before thrombectomy than alteplase [21]. Moreover, in a drip-and-ship cohort, early recanalization rates were similar between tenecteplase and alteplase (21.4% vs. 18.3%), but the findings suggested that tenecteplase may still achieve recanalization earlier because it is delivered as a single bolus [22]. Taken together, these findings support the possibility that, even among patients eligible for endovascular thrombectomy, the advantage of tenecteplase may lie not only in its pharmacologic profile but also in its ability to provide immediate full-dose thrombolysis without infusion-related workflow constraints.

Alteplase also appears to induce greater systemic fibrinolytic disturbance than tenecteplase, including more pronounced fibrinogen depletion. Although this does not necessarily imply a large difference in intracranial bleeding risk in every trial, it reinforces the biologic rationale for preferring a more fibrin-selective agent [23].

Structural modifications from alteplase

Alteplase, a second-generation tissue-type plasminogen activator (tPA), is a multidomain serine protease composed of five functional domains: an N-terminal finger domain, an epidermal growth factor (EGF)-like domain, kringle 1, kringle 2, and a C-terminal serine protease domain (Figure 1) [24]. The finger domain is the major fibrin-binding region and helps localize tPA to the thrombus surface, and the EGF-like domain contributes to receptor interactions and hepatic clearance. Kringle 1 is involved in clearance-related interactions and structural modulation of the molecule, kringle 2 stabilizes fibrin-dependent plasminogen activation and contributes to assembly of the fibrin-tPA-plasminogen ternary complex, and the serine protease domain contains the catalytic site responsible for conversion of plasminogen to plasmin [25]. Thus, although the entire molecule participates in fibrinolysis, the key engineering advances in tenecteplase were concentrated in the kringle 1 domain, which contributes to its prolonged half-life, and the serine protease domain, which enhances fibrin specificity.

Figure 1.

Structural modifications of tenecteplase and their pharmacologic and practical implications. The figure compares the domain structure of alteplase and tenecteplase, highlighting the three engineered substitutions in tenecteplase (T103N, N117Q, and KHRR296-299AAAA). These modifications are associated with increased fibrin specificity, greater resistance to PAI-1, prolonged plasma half-life, and reduced systemic fibrinolysis. The lower panel also illustrates the difference in stroke dosing and administration, with alteplase requiring bolus plus 60-minute infusion and tenecteplase given as a single bolus. EGF, epidermal growth factor; TNK, tenecteplase; PAI-1, plasminogen activator inhibitor-1.

Similar to alteplase, tenecteplase exerts its thrombolytic effect by binding fibrin and catalyzing the conversion of plasminogen to plasmin, which then degrades the fibrin meshwork of thrombi [23,26]. To retain this fibrinolytic mechanism while improving its pharmacologic properties, tenecteplase was engineered as a genetically modified variant of alteplase through three amino acid substitutions: T103N, N117Q, and replacement of the KHRR sequence at residues 296 to 299 with tetra-alanine residues (Figure 1) [14]. Although the T103N substitution primarily reduces plasma clearance by introducing an additional glycosylation site in kringle 1, it inherently impairs fibrin binding and clot lysis [12,13]. The N117Q substitution overcomes this limitation by removing the native glycosylation site at position 117, thereby restoring fibrin affinity and preserving fibrinolytic activity while also slowing plasma clearance [14]. The KHRR296-299AAAA substitution in the serine protease domain provides the major functional advantages of tenecteplase by markedly increasing fibrin specificity, enhancing fibrinogen conservation, and conferring approximately 80-fold greater resistance to PAI-1 [12]. By modifying clearance-related and catalytic domains, tenecteplase achieves greater thrombus selectivity and a longer plasma half-life [27,28].

Preclinical development and early pharmacological profiling

The preclinical development of tenecteplase established the biologic rationale that later supported its clinical translation in acute ischemic stroke. The key preclinical studies of tenecteplase are summarized in Table 1. Although the number of animal studies is smaller than the eventual clinical literature, the available preclinical work is unusually coherent. Early studies showed that molecular engineering could simultaneously reduce plasma clearance, preserve fibrinolytic activity, increase fibrin specificity, and enhance resistance to PAI-1; subsequently, later stroke models demonstrated favorable thrombolytic performance, acceptable hemorrhagic profiles, and, more recently, potential advantages in brain-cell toxicity and multicenter reproducibility.

Key preclinical animal studies of tenecteplase in thrombosis and ischemic stroke models

Molecular and pharmacologic proof of concept

In a foundational 1994 preclinical study using rabbit models [14], tenecteplase showed markedly slower in vivo clearance than wild-type tPA while retaining near-normal fibrin binding and plasma clot lysis activity. Specifically, plasma clearance of the final tenecteplase construct was approximately 8.4-fold lower than that of wild-type tPA (1.9 vs. 16.1 mL/min/kg). Fifteen minutes after intravenous bolus injection, about 50% of tenecteplase remained in the circulation, compared with only about 1% of wild-type tPA [14]. This study also demonstrated that tenecteplase was substantially more clot-selective than wild-type tPA. The triple mutant exhibited approximately 80-fold greater resistance to PAI-1 and roughly 14-fold enhanced relative fibrin specificity. These findings were critical because they showed that tenecteplase did not merely last longer in the circulation; it also retained effective thrombolytic activity while producing less systemic fibrinolysis.

Arterial recanalization and systemic safety in rabbit thrombosis models

The next major step was to determine whether the molecular advantages of tenecteplase translated into more effective recanalization under arterial thrombosis conditions. A rabbit arterial occlusion study compared bolus tenecteplase with recombinant human tPA [28]. In that study, tenecteplase produced faster and more complete recanalization of occluded arteries than tPA, without increasing systemic plasmin generation or peripheral bleeding. The authors additionally reported that, unlike tPA, tenecteplase did not potentiate collagen-induced platelet aggregation in human plasma. These results extended the findings of earlier molecular work by showing that the favorable pharmacokinetics/pharmacodynamics (PK/PD) profile of tenecteplase was not merely a laboratory phenomenon but translated into superior recanalization efficiency in an in vivo arterial model. These findings in the rabbit model are significant for two primary reasons. First, the study showed that bolus tenecteplase could outperform infusion-based tPA in restoring arterial patency, reinforcing the therapeutic relevance of reduced clearance and higher clot selectivity. Second, the absence of excess systemic plasmin generation or peripheral bleeding suggested that tenecteplase might improve thrombolysis without proportionally increasing systemic hemorrhagic liability. In retrospect, these findings anticipated the later clinical argument that the practical advantage of tenecteplase as a single-bolus agent is inseparable from its biologic advantage as a more thrombus-selective fibrinolytic.

Transition to embolic stroke models

The stroke-specific preclinical literature subsequently evaluated whether the pharmacologic advantages of tenecteplase would translate into embolic stroke models. In that setting, tenecteplase achieved recanalization rates comparable to wild-type tPA while producing a numerically lower rate of cerebral hemorrhage, suggesting a more favorable safety profile despite similar thrombolytic efficacy [29]. These observations were later extended in a smallclot embolic stroke model by demonstrating that tenecteplase had a more favorable overall pharmacological profile than alteplase, with implications not only for thrombolysis but also for overall neurological recovery and survival [15]. Taken together, these studies indicated that the favorable properties of tenecteplase were preserved in embolic stroke models, supporting its translational relevance to ischemic stroke.

Recent multicenter preclinical reassessment

After these early rabbit studies, the preclinical literature directly comparing alteplase and tenecteplase remained relatively sparse for many years. A major modern contribution came from a multicenter preclinical comparison of tenecteplase and alteplase in a mouse model of acute ischemic stroke [30]. This work is notable for revisiting tenecteplase within a modern experimental framework, incorporating parallel evaluations at two independent preclinical centers and utilizing both in vivo and in vitro models. According to the report, a single bolus dose of tenecteplase at 2.5 mg/kg achieved infarct reduction similar to that obtained with 10 mg/kg of alteplase, and early tenecteplase administration was associated with fewer hemorrhagic transformations than early alteplase administration, although this advantage was not maintained in the late treatment condition. The study also evaluated toxicity in endothelial cells, astrocytes, and neurons, and reported less neuronal cell death with tenecteplase than with alteplase. Overall, the authors concluded that these two independent preclinical studies supported tenecteplase as a promising reperfusion alternative to alteplase.

These preclinical findings should nevertheless be interpreted in the context of substantial model heterogeneity. The studies used different arterial occlusion and embolic stroke models including variation in clot size and composition, vascular anatomy, treatment timing, and thrombolytic dosing. Moreover, experimental animals generally do not reproduce the advanced age, vascular comorbidities, collateral variability, and extent of blood-brain barrier injury observed in patients with acute ischemic stroke. Thus, favorable recanalization and hemorrhagic profiles in these models provide important mechanistic and translational support but cannot directly predict clinical efficacy or symptomatic intracranial hemorrhage risk.

PK/PD outcome of tenecteplase

Human PK/PD evidence for tenecteplase has evolved in a stepwise translational fashion. The earliest human studies were conducted in AMI, where tenecteplase was first developed and evaluated as a single-bolus fibrinolytic rather than an infusion-based thrombolytic. In that context, early dose-ranging clinical trials established the feasibility of bolus-only delivery [31,32]. Subsequent larger clinical PK/PD analyses in patients with AMI utilized plasma concentration-time data from 179 individuals. Pharmacokinetically, tenecteplase exhibited biphasic disposition, with a dominant early half-life of approximately 17–24 minutes and a terminal half-life of approximately 65–132 minutes. In practical terms, the initial half-life reflects the rapid early decline in plasma concentration immediately after bolus administration, whereas the terminal half-life reflects the slower late-phase elimination of the remaining drug. This biphasic profile helps maintain therapeutically meaningful plasma exposure after a single bolus dose [33]. The stroke-specific PK/PD literature emerged later. The ATTEST (Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis) biomarker substudy demonstrated that in patients with acute ischemic stroke, alteplase 0.9 mg/kg induced broader systemic changes in coagulation and fibrinolysis than tenecteplase 0.25 mg/kg. Specifically, alteplase was associated with significant reductions in plasma fibrinogen, plasminogen, and factor V, as well as prolongation of prothrombin time, whereas tenecteplase caused only minor plasminogen reduction with substantially less fibrinogen and plasminogen consumption. These findings are consistent with clinical expression of the enhanced fibrin specificity conferred largely by the KHRR296-299AAAA substitution, as reflected by less systemic plasminogen activation and fibrinogen consumption in patients with acute ischemic stroke. This supports the concept that tenecteplase is not only pharmacokinetically more convenient but also pharmacodynamically more clot-selective in the stroke setting [34].

Evolution of tenecteplase dosing

Antecedent cardiology experience

Before its formal development in stroke, tenecteplase had already been clinically validated in AMI as a single-bolus thrombolytic. Early thrombolysis in myocardial infarction (TIMI) studies established the feasibility of bolus-only administration and suggested that doses in the 30–50 mg range could achieve effective reperfusion with limited systemic fibrinolytic disturbance [32,35]. In TIMI 10B, the 40 mg dose showed angiographic efficacy essentially equivalent to accelerated alteplase, while the 50 mg dose raised safety concerns, thereby establishing 40 mg as the preferred dose for subsequent cardiology trials [35,36].

This dose was then carried forward into ASSENT-2 (Assessment of the Safety and Efficacy of a New Thrombolytic) trial, in which tenecteplase was administered as a weight-adjusted single bolus of approximately 0.5–0.53 mg/kg and proved therapeutically equivalent to alteplase for 30-day mortality, with similar intracranial hemorrhage but less non-cerebral bleeding (26.4% vs. 28.9%), reinforcing the practical and safety advantages of a bolus-only fibrinolytic strategy [37]. One-year follow-up analysis of the ASSENT-2 trial further strengthened the cardiology case for tenecteplase. At one year, overall mortality remained similar between tenecteplase and alteplase, confirming that the short-term equivalence observed in the original trial was maintained over time [38]. Importantly, this cardiology experience validated tenecteplase as a large-scale, bolus-only fibrinolytic but also showed that the fixed 40-mg or approximately 0.5 mg/kg regimen used in AMI could not be directly extrapolated to acute ischemic stroke, where intracranial bleeding risk and differences in target vascular beds necessitated a more prolonged dose-finding process. This background helps explain why dose exploration became a central issue in stroke development, rather than a simple extension of the AMI program.

Early phase II dose exploration trials in acute ischemic stroke

Early phase II studies of tenecteplase in acute ischemic stroke were primarily designed to determine whether this genetically modified fibrinolytic could be administered safely across a clinically meaningful dose range and whether any particular dose showed a favorable biological or clinical signal. The initial pilot dose-escalation study examined doses from 0.1 to 0.4 mg/kg and found them sufficiently safe for further comparative evaluation [39]. This early work did not identify a single optimal dose, but it established the foundation for subsequent randomized clinical trials by showing that tenecteplase was feasible in the stroke setting and that formal dose selection was both possible and necessary.

Subsequent randomized phase II studies progressively narrowed the field toward 0.25 mg/kg (Table 2). The TNK-S2B (Phase 2B Study of Tenecteplase in Acute Ischemic Stroke) trial compared 0.1, 0.25, and 0.4 mg/kg tenecteplase with alteplase in a seamless phase IIb/III design, and although it was terminated early, it provided an important signal against the 0.4 mg/kg dose because of a higher rate of symptomatic intracranial hemorrhage [40]. A phase IIb TAAIS (Tenecteplase versus Alteplase for Acute Ischemic Stroke) trial in perfusion-selected patients with vessel occlusion then compared 0.1 and 0.25 mg/kg tenecteplase against alteplase and demonstrated superior reperfusion and better clinical outcomes with tenecteplase, helping position 0.25 mg/kg as the leading candidate dose [41]. More recently, TRACE (Tenecteplase Reperfusion therapy in Acute ischemic Cerebrovascular Events), a multicenter phase II trial in China comparing 0.1, 0.25, and 0.32 mg/kg tenecteplase with alteplase, further supported this direction by suggesting that 0.25 mg/kg provided the most encouraging numerical efficacy-safety balance among the tenecteplase doses tested, although no significant between-group differences were observed [42].

Dose exploration studies of tenecteplase

Additional phase II studies helped reinforce, rather than redefine, this emerging dose preference. ATTEST evaluated 0.25 mg/kg tenecteplase against alteplase in a broader 4.5-hour thrombolysis population and found similar penumbral salvage, clinical outcomes, and safety, thereby supporting the generalizability of this dose beyond highly selected imaging-based cohorts [43]. Likewise, a smaller supportive study in minor stroke with proven occlusion suggested that 0.25 mg/kg remained feasible and promising in other clinical subgroups [44]. In addition, the phase II TASTE-A (Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance) trial showed that prehospital administration of 0.25 mg/kg tenecteplase while in transit aboard the Melbourne Mobile Stroke Unit was associated with a smaller post-treatment perfusion lesion volume, greater ultra-early clinical recovery, and no excess safety signal compared with alteplase, further supporting the practical and biological validity of this dose in ultra-early stroke care [45]. Although CHABLIS-T (Chinese Acute Tissue-Based Imaging Selection for Lysis in Stroke-Tenecteplase) trial differed in design and focused on a highly selected, perfusion imaging-defined population treated in the extended 4.5–24 hour window, it similarly suggested promise for both 0.25 mg/kg and 0.32 mg/kg without demonstrating a clear advantage of the higher dose [46]. Consequently, these phase II studies did not identify 0.25 mg/kg through a single decisive comparison; rather, they produced a process of convergence in which 0.1 mg/kg appeared less compelling, 0.4 mg/kg lacked a convincing advantage, and 0.25 mg/kg emerged as the most balanced dose to carry forward into later confirmatory trials [47].

Convergence on 0.25 mg/kg: transitional phase II and III trials

Following early dose-exploration studies, the next critical step in tenecteplase development was not simply to confirm efficacy, but to determine which dose should be carried forward into later-phase trials and clinical practice. Among the studies that shaped this transition, EXTEND-IA TNK Part 1, EXTEND-IA TNK Part 2, Norwegian Tenecteplase Stroke Trial (NOR-TEST), and NOR-TEST 2A were particularly influential (Table 3). Overall, these trials helped establish 0.25 mg/kg as the preferred dose by demonstrating its efficacy, the absence of additional benefit with escalation to 0.4 mg/kg, and safety concerns with the higher dose, particularly in older patients [48].

Transitional phase II-III trials that established 0.25 mg/kg as the preferred tenecteplase dose in acute ischemic stroke

EXTEND-IA TNK Part 1 provided the first strong randomized evidence supporting tenecteplase 0.25 mg/kg in patients with large-vessel occlusion undergoing endovascular thrombectomy. 21 In this phase II trial, tenecteplase was compared directly with standard-dose alteplase and was associated with a higher rate of reperfusion before endovascular thrombectomy as well as better functional outcome at 90 days. Although the trial population was highly selected, particularly through vessel imaging and thrombectomy eligibility, the study established that 0.25 mg/kg was an active and clinically meaningful dose in a setting where rapid early reperfusion is especially relevant. EXTEND-IA TNK Part 2 then addressed a more focused question: whether increasing the tenecteplase dose from 0.25 mg/kg to 0.4 mg/kg could further improve reperfusion before endovascular thrombectomy. The answer was essentially no. In this phase II dose-comparison trial, the higher dose did not improve the proportion of patients achieving substantial reperfusion before endovascular thrombectomy [49]. This finding was highly important for dose selection, because it showed that simple dose escalation did not translate into greater efficacy in a biologically favorable population. In other words, 0.25 mg/kg appeared sufficient, whereas 0.4 mg/kg failed to demonstrate added value [48].

The role of NOR-TEST and NOR-TEST 2A in dose selection was somewhat different. Rather than supporting 0.25 mg/kg directly, these trials helped define what should not be taken forward. NOR-TEST, the first phase III trial comparing tenecteplase 0.4 mg/kg with alteplase, failed to demonstrate the prespecified superiority hypothesis, although efficacy and safety outcomes were generally comparable between the two groups; however, interpretation was limited by the large proportion of patients with mild stroke [50]. As a result, NOR-TEST did not convincingly validate 0.4 mg/kg as the optimal dose for broad stroke practice. That uncertainty became much more clinically consequential with NOR-TEST 2A, another phase III trial that enrolled patients with moderate-to-severe acute ischemic stroke. In contrast to the relatively neutral signal from NOR-TEST, NOR-TEST 2A was stopped early and showed worse outcomes with tenecteplase 0.4 mg/kg than with alteplase, including excess symptomatic or any intracranial hemorrhage and poorer functional outcome [51]. These data substantially weakened the case for the higher dose and shifted the field away from 0.4 mg/kg [52].

The harm observed with tenecteplase 0.4 mg/kg may reflect a dose-dependent narrowing of its therapeutic margin. At higher exposure, the molecular advantage of fibrin specificity may be insufficient to prevent off-target fibrinolysis and bleeding from ischemia-injured cerebral microvasculature. Although this mechanism remains inferential, it may explain why dose escalation increased hemorrhagic risk without improving reperfusion.

Therefore, the emergence of 0.25 mg/kg as the preferred tenecteplase dose was driven not only by efficacy, but also by the absence of benefit with dose escalation and the growing evidence of harm at 0.4 mg/kg. This sequence of evidence strongly influenced the design of subsequent phase III trials, most of which adopted 0.25 mg/kg as the dose to be tested against alteplase in routine acute ischemic stroke care.

Non-inferiority of tenecteplase in phase III trials

Recent phase III trials have substantially strengthened the evidence base for tenecteplase as an alternative to alteplase for acute ischemic stroke within 4.5 hours of onset (Table 4) [53]. Across Alteplase Compared with Tenecteplase (AcT), TRACE-2, ATTEST-2, ORIGINAL (Optimal Reperfusion Strategy in Acute Ischemic Stroke with Low-Dose Tenecteplase), and TASTE (Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation), tenecteplase at 0.25 mg/kg consistently met non-inferiority criteria against standard-dose alteplase (although TASTE achieved non-inferiority only in the per-protocol analysis), while major safety outcomes such as symptomatic intracranial hemorrhage and mortality were generally similar between groups. This similarity in intracranial bleeding risk, despite the greater fibrin specificity and reduced systemic fibrinolytic effects of tenecteplase, highlights that symptomatic intracranial hemorrhage is influenced by factors beyond systemic fibrinolysis. These include infarct extent, blood-brain barrier disruption, reperfusion injury, treatment timing, blood pressure, and concomitant endovascular thrombectomy [54]. Thus, the pharmacodynamic selectivity of tenecteplase may reduce systemic fibrinolytic disturbance without consistently lowering symptomatic intracranial hemorrhage across clinical settings.

Characteristics and outcomes of phase III non-inferiority trials comparing tenecteplase 0.25 mg/kg with alteplase in acute ischemic stroke

Trial-specific characteristics and outcomes

AcT trial was the first large pragmatic phase III study to show that tenecteplase could be used in broad real-world practice. It enrolled 1,600 patients in Canada, of whom 1,577 were included in the intention-to-treat population, and found that excellent functional outcome (modified Rankin Scale [mRS] 0–1) occurred in 36.9% of the tenecteplase group and 34.8% of the alteplase group, meeting the prespecified non-inferiority margin, with similar safety outcomes [55]. Its major strength was external validity: it reflected routine stroke thrombolysis practice in a broadly eligible population rather than a highly selected cohort with restrictive inclusion criteria [56]. TRACE-2 trial extended this evidence to a large Chinese population. In patients who were intravenous thrombolysis-eligible but ineligible for endovascular thrombectomy, tenecteplase remained non-inferior to alteplase, with 62% vs. 58% achieving mRS 0–1 at 90 days and comparable symptomatic intracranial hemorrhage rates of about 2% in both groups [57]. ATTEST-2 trial was methodologically notable because it used the full 90-day mRS distribution as the primary endpoint rather than a dichotomized threshold. Tenecteplase was non-inferior to alteplase with an odds ratio of 1.07 (95% CI 0.90–1.27), but superiority was not established [58]. ORIGINAL trial provided another Chinese phase III confirmation. In this trial, 72.7% of tenecteplase-treated patients and 70.3% of alteplase-treated patients achieved the primary endpoint, and non-inferiority was met with similar symptomatic intracranial hemorrhage rates (1.2% vs. 1.2%). The absolute outcome rates were much better than in AcT trial, likely reflecting lower baseline severity and a somewhat different enrolled population [59]. TASTE trial is the key counterbalance in this literature. Unlike the broader pragmatic trials, TASTE trial enrolled patients with salvageable tissue demonstrated on perfusion imaging, making it the most imaging-enriched phase III tenecteplase trial in the early time window. In the intention-to-treat population, tenecteplase did not meet the prespecified non-inferiority threshold for no disability at 90 days, although the per-protocol analysis supported non-inferiority and safety outcomes were similar [60]. Thus, the TASTE trial suggests that the non-inferiority of tenecteplase to alteplase may not uniformly generalize to all specific imaging-selected subgroups.

Robustness of phase III evidence

The strength of the recent evidence base lies in its reproducibility. Tenecteplase has not been supported by a single isolated positive study, but by multiple phase III randomized comparisons across distinct populations [61]. This consistency has shifted the clinical discussion away from whether tenecteplase is a credible alteplase alternative and toward identifying the patient groups and workflows in which it may be preferable. At present, the totality of evidence supports tenecteplase 0.25 mg/kg as a practical and evidence-based non-inferior alternative to alteplase for intravenous thrombolysis in acute ischemic stroke [62]. This accumulated phase III evidence culminated in the U.S. Food and Drug Administration approval of tenecteplase for the treatment of acute ischemic stroke in adults in March 2025. On this basis, guideline recommendations that historically centered on alteplase for intravenous thrombolysis within 4.5 hours of symptom onset have increasingly been extended to include tenecteplase 0.25 mg/kg as an accepted alternative [2,63-65].

Current recommendations differ primarily in whether tenecteplase is preferred for patients proceeding to thrombectomy. The American Heart Association/American Stroke Association guideline and the Canadian Stroke Best Practice Recommendations consider tenecteplase 0.25 mg/kg and alteplase 0.9 mg/kg acceptable options for eligible patients within 4.5 hours, without specifically preferring tenecteplase in thrombectomy candidates [2,64]. In contrast, the European Stroke Organisation recommends tenecteplase 0.25 mg/kg over alteplase in patients with large-vessel occlusion proceeding to thrombectomy, while recognizing it as an alternative in the broader thrombolysis-eligible population [63]. The Korean Stroke Society scientific statement similarly supports tenecteplase as an alternative to alteplase in general and considers it probably superior in thrombectomy-eligible large-vessel occlusion [65].

Accumulated randomized evidence and study-level meta-analyses have largely established tenecteplase 0.25 mg/kg as a clinically effective alternative, and its implementation has already occurred across many stroke systems. The more relevant contemporary questions are therefore how reperfusion outcomes can be improved beyond those achieved with tenecteplase through alternative or adjunctive lytic strategies, and whether treatment effects vary across clinical contexts [66-70]. These contexts include imaging-based selection, endovascular thrombectomy availability and candidacy, occlusion location, stroke severity, treatment window, and workflow demands. Future investigations should focus on these sources of treatment-effect heterogeneity and on strategies that further improve early reperfusion without increasing hemorrhagic risk.

Extended-window tenecteplase thrombolysis

Randomized evidence for intravenous tenecteplase between 4.5 and 24 hours after stroke onset has yielded heterogeneous findings, suggesting that treatment effects depend on imaging selection, occlusion pattern, and access to endovascular thrombectomy (Table 5) [71]. Early imaging-selected studies, including ROSE-TNK (MRI-guided thrOmbolysis for Stroke bEyond Time Window by Tenecteplase) and CHABLIS-T II trials, supported the feasibility and biological activity of late-window tenecteplase but did not establish definitive functional benefit [72,73]. ROSE-TNK trial used diffusion-weighted imaging-fluid-attenuated inversion recovery mismatch, whereas CHABLIS-T II trial enrolled patients with large- or medium-vessel occlusion and a favorable perfusion profile and used an imaging-based reperfusion outcome.

Characteristics and outcomes of randomized trials of intravenous tenecteplase in the extended time window

More favorable clinical results emerged when thrombectomy was unavailable or not indicated. TRACE-III trial improved functional outcomes in perfusion-selected patients with anterior-circulation large-vessel occlusion who lacked access to thrombectomy [74]. OPTION (Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke) trial similarly demonstrated benefit in patients with salvageable tissue but without thrombectomy-eligible large-vessel occlusion, although symptomatic intracranial hemorrhage was increased [75].

By contrast, TIMELESS (Thrombolysis in Imaging-Eligible, Late-Window Patients to Assess the Efficacy and Safety of Tenecteplase) and TNK-PLUS (Endovascular Treatment With or Without Preceding Intravenous Tenecteplase in Patients With Late-Window Acute Ischemic Stroke Due to Middle Cerebral Artery Occlusion) trials did not demonstrate additional functional benefit when thrombectomy was readily available and performed in most or all patients [76,77]. Collectively, these findings suggest that late-window tenecteplase has the greatest potential when viable tissue is demonstrated and no timely endovascular reperfusion option is available, whereas its incremental value appears limited when thrombectomy can be performed promptly.

Conclusions

The development of tenecteplase in acute ischemic stroke represents a successful translation from molecular engineering to clinical stroke care. Its prolonged half-life, increased fibrin specificity, and greater resistance to PAI-1 addressed several of the core pharmacologic limitations of alteplase and enabled single-bolus administration.

Building on these molecular and pharmacologic properties, the subsequent clinical development of tenecteplase required careful identification of a stroke-specific dose that preserved efficacy while maintaining an acceptable safety margin. The identification of 0.25 mg/kg as the preferred dose was therefore a critical step in translating the pharmacologic advantages of tenecteplase into clinical stroke therapy.

With this dose established, subsequent large randomized trials across multiple countries and study-level meta-analyses provide consistent evidence that tenecteplase 0.25 mg/kg is non-inferior to alteplase for acute ischemic stroke. Accordingly, tenecteplase should currently be regarded as a practical, evidence-based alternative to alteplase rather than as a universally adopted replacement. Its single-bolus administration offers particular practical advantages in workflow-limited and thrombectomy-eligible settings.

Although tenecteplase has improved molecular and pharmacologic properties compared with alteplase, clinical trials have established non-inferiority rather than superiority. This apparent gap between pharmacologic advantages and clinical outcomes highlights the need for further investigation to identify the specific patient populations and clinical settings in which the molecular and pharmacologic advantages of tenecteplase may translate into meaningful benefits over alteplase.

Future research should focus on alternative or adjunctive lytic strategies that improve upon tenecteplase and on defining how treatment effects vary according to imaging selection, thrombectomy access, occlusion pattern, and workflow context.

Notes

Funding statement

None

Conflicts of interest

The authors have no financial conflicts of interest.

Author contribution

Conceptualization: Jae Wook Jung, Jin Soo Lee. Study design: Jae Wook Jung, Jin Soo Lee. Methodology: Jae Wook Jung, Jin Soo Lee. Data collection: Jae Wook Jung, Jin Soo Lee. Writing—original draft: Jae Wook Jung, Jin Soo Lee. Writing—review & editing: Jae Wook Jung, Jin Soo Lee. Approval of final manuscript: Jae Wook Jung, Jin Soo Lee.

Acknowledgments

We thank the Medical Illustration & Design team at the Medical Research Support Services of Yonsei University College of Medicine for their excellent medical illustrations.

References

1. Berge E, Whiteley W, Audebert H, De Marchis GM, Fonseca AC, Padiglioni C, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J 2021;6:I–LXII.
2. Prabhakaran S, Gonzalez NR, Zachrison KS, Adeoye O, Alexandrov AW, Ansari SA, et al. 2026 Guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association/American Stroke Association. Stroke 2026;57:e316–e436.
3. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632–640.
4. Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992;23:641–645.
5. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
6. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999;340:1781–1787.
7. Xu Y, Hu Y, Wu G, Niu L, Fang C, Li Y, et al. Specific inhibition on PAI-1 reduces the dose of alteplase for ischemic stroke treatment. Int J Biol Macromol 2024;257:128618.
8. Singh N, Menon BK, Dmytriw AA, Regenhardt RW, Hirsch JA, Ganesh A. Replacing alteplase with tenecteplase: is the time ripe? J Stroke 2023;25:72–80.
9. Ospel JM, Singh N, Almekhlafi MA, Menon BK, Butt A, Poppe AY, et al. Early recanalization with alteplase in stroke because of large vessel occlusion in the ESCAPE trial. Stroke 2021;52:304–307.
10. Wang L, Hao M, Wu N, Wu S, Fisher M, Xiong Y. Comprehensive review of tenecteplase for thrombolysis in acute ischemic stroke. J Am Heart Assoc 2024;13e031692.
11. Acheampong P, May MT, Ford GA, Dixit AK. Bolus-infusion delays of alteplase during thrombolysis in acute ischaemic stroke and functional outcome at 3 months. Stroke Res Treat 2014;2014:358640.
12. Paoni NF, Keyt BA, Refino CJ, Chow AM, Nguyen HV, Berleau LT, et al. A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA). Thromb Haemost 1993;70:307–312.
13. Refino CJ, Paoni NF, Keyt BA, Pater CS, Badillo JM, Wurm FM, et al. A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost 1993;70:313–319.
14. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994;91:3670–3674.
15. Lapchak PA, Araujo DM, Zivin JA. Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol 2004;185:154–159.
16. Miller SE, Warach SJ. Evolving thrombolytics: from alteplase to tenecteplase. Neurotherapeutics 2023;20:664–678.
17. Davydov L, Cheng JW. Tenecteplase: a review. Clin Ther 2001;23:982–997.
18. Smith C, Al-Nuaimi Y, Wainwright J, Sherrington C, Singh A, Kallingal J, et al. The influence of bolus to infusion delays on plasma tissue plasminogen activator levels. Int J Stroke 2014;9:939–942.
19. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018;49:e46–e99.
20. Warach SJ, Dula AN, Milling TJ, Miller S, Allen L, Zuck ND, et al. Prospective observational cohort study of tenecteplase versus alteplase in routine clinical practice. Stroke 2022;53:3583–3593.
21. Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med 2018;378:1573–1582.
22. Seners P, Caroff J, Chausson N, Turc G, Denier C, Piotin M, et al. Recanalization before thrombectomy in tenecteplase vs. alteplase-treated drip-and-ship patients. J Stroke 2019;21:105–107.
23. Bivard A, Lin L, Parsons MW. Review of stroke thrombolytics. J Stroke 2013;15:90–98.
24. Mican J, Toul M, Bednar D, Damborsky J. Structural biology and protein engineering of thrombolytics. Comput Struct Biotechnol J 2019;17:917–938.
25. Longstaff C, Thelwell C, Williams SC, Silva MM, Szabó L, Kolev K. The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. Blood 2011;117:661–668.
26. Barreto AD. Intravenous thrombolytics for ischemic stroke. Neurotherapeutics 2011;8:388–399.
27. Tsikouris JP, Jackson KC, Fike DS, Cox CD, Meyerrose GE, Seifert CF. Thrombolytic fibrin specificity influences activated partial thromboplastin time prolongation in vitro. Blood Coagul Fibrinolysis 2002;13:725–731.
28. Benedict CR, Refino CJ, Keyt BA, Pakala R, Paoni NF, Thomas GR, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995;92:3032–3040.
29. Chapman DF, Lyden P, Lapchak PA, Nunez S, Thibodeaux H, Zivin J. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke 2001;32:748–752.
30. Correa-Paz C, Pérez-Mato M, Bellemain-Sagnard M, González-Domínguez M, Marie P, Pérez-Gayol L, et al. Pharmacological preclinical comparison of tenecteplase and alteplase for the treatment of acute stroke. J Cereb Blood Flow Metab 2024;44:1306–1318.
31. Modi NB, Fox NL, Clow FW, Tanswell P, Cannon CP, Van de Werf F, et al. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol 2000;40:508–515.
32. Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, et al. TNK-tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997;95:351–356.
33. Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 2002;41:1229–1245.
34. Huang X, Moreton FC, Kalladka D, Cheripelli BK, MacIsaac R, Tait RC, et al. Coagulation and fibrinolytic activity of tenecteplase and alteplase in acute ischemic stroke. Stroke 2015;46:3543–3546.
35. Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation 1998;98:2805–2814.
36. Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. Am Heart J 1999;137:786–791.
37. Van De Werf F, ; Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354:716–722.
38. Sinnaeve P, Alexander J, Belmans A, Bogaerts K, Langer A, Diaz R, et al. One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. Am Heart J 2003;146:27–32.
39. Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM; TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005;36:607–612.
40. Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010;41:707–711.
41. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012;366:1099–1107.
42. Li S, Pan Y, Wang Z, Liang Z, Chen H, Wang D, et al. Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study. Stroke Vasc Neurol 2022;7:47–53.
43. Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol 2015;14:368–376.
44. Coutts SB, Dubuc V, Mandzia J, Kenney C, Demchuk AM, Smith EE, et al. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke 2015;46:769–774.
45. Bivard A, Zhao H, Churilov L, Campbell BCV, Coote S, Yassi N, et al. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial. Lancet Neurol 2022;21:520–527.
46. Cheng X, Hong L, Churilov L, Lin L, Ling Y, Zhang J, et al. Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial. Stroke Vasc Neurol 2024;9:551–559.
47. Huang X, MacIsaac R, Thompson JL, Levin B, Buchsbaum R, Haley EC Jr, et al. Tenecteplase versus alteplase in stroke thrombolysis: an individual patient data meta-analysis of randomized controlled trials. Int J Stroke 2016;11:534–543.
48. Yogendrakumar V, Churilov L, Mitchell PJ, Kleinig TJ, Yassi N, Thijs V, et al. Safety and efficacy of tenecteplase in older patients with large vessel occlusion: a pooled analysis of the EXTEND-IA TNK trials. Neurology 2022;98:e1292–e1301.
49. Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial. JAMA 2020;323:1257–1265.
50. Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Rønning OM, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol 2017;16:781–788.
51. Kvistad CE, Næss H, Helleberg BH, Idicula T, Hagberg G, Nordby LM, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, noninferiority trial. Lancet Neurol 2022;21:511–519.
52. Novotny V, Kvistad CE, Naess H, Logallo N, Fromm A, Khanevski AN, et al. Tenecteplase, 0.4 mg/kg, in moderate and severe acute ischemic stroke: a pooled analysis of NOR-TEST and NOR-TEST 2A. J Am Heart Assoc 2023;12e030320.
53. Li L, Lioutas VA, Akyea RK, Gerner S, Lau KK, Ramage E, et al. Non-inferiority trials in stroke research: what are they, and how should we interpret them? J Stroke 2025;27:41–51.
54. Chen JH, Su IC, Lu YH, Hsieh YC, Chen CH, Lin CJ, et al. Predictive modeling of symptomatic intracranial hemorrhage following endovascular thrombectomy: insights from the nationwide TREAT-AIS registry. J Stroke 2025;27:85–94.
55. Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet 2022;400:161–169.
56. Nair R, Singh N, Kate M, Asdaghi N, Sarmiento R, Bala F, et al. Intravenous tenecteplase compared with alteplase for minor ischaemic stroke: a secondary analysis of the AcT randomised clinical trial. Stroke Vasc Neurol 2024;9:604–612.
57. Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet 2023;401:645–654.
58. Muir KW, Ford GA, Ford I, Wardlaw JM, McConnachie A, Greenlaw N, et al. Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial. Lancet Neurol 2024;23:1087–1096.
59. Meng X, Li S, Dai H, Lu G, Wang W, Che F, et al. Tenecteplase vs alteplase for patients with acute ischemic stroke: the ORIGINAL randomized clinical trial. JAMA 2024;332:1437–1445.
60. Parsons MW, Yogendrakumar V, Churilov L, Garcia-Esperon C, Campbell BCV, Russell ML, et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial. Lancet Neurol 2024;23:775–786.
61. Koh JH, Lim CYJ, Tan LTP, Sia CH, Poh KK, Sharma VK, et al. Ethnic differences in the safety and efficacy of tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis. J Stroke 2024;26:371–390.
62. Palaiodimou L, Katsanos AH, Turc G, Asimakopoulos AG, Mavridis D, Schellinger PD, et al. Tenecteplase vs alteplase in acute ischemic stroke within 4.5 hours: a systematic review and meta-analysis of randomized trials. Neurology 2024;103e209903.
63. Alamowitch S, Turc G, Palaiodimou L, Bivard A, Cameron A, De Marchis GM, et al. European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. Eur Stroke J 2023;8:8–54.
64. Heran M, Lindsay P, Gubitz G, Yu A, Ganesh A, Lund R, et al. Canadian stroke best practice recommendations: acute stroke management, 7th edition practice guidelines update, 2022. Can J Neurol Sci 2024;51:1–31.
65. Kim H, Kim JT, Kim BJ, Kim DH, Kim C, Choi JC, et al. Tenecteplase in acute ischemic stroke: a scientific statement from the Korean Stroke Society. J Clin Neurol 2025;21:384–396.
66. Siddiqi AZ, Ignacio K, Kaveeta C, Bala F, Ademola A, Tkach A, et al. Thrombolysis in patients with versus without visible occlusion: a secondary analysis from the AcT trial. J Stroke 2025;27:113–117.
67. Bala F, Singh N, Ignacio K, Alhabli I, Ademola A, Alrohimi A, et al. Tenecteplase versus alteplase in medium vessel occlusion ischemic stroke: a secondary analysis of the alteplase compared to tenecteplase randomized trial. J Stroke 2024;26:280–289.
68. Huang J, Yang J, Liu C, Li L, Yang D, Guo C, et al. Intra-arterial tenecteplase following endovascular reperfusion for large vessel occlusion acute ischemic stroke: the POST-TNK randomized clinical trial. JAMA 2025;333:579–588.
69. Miao Z, Luo G, Song L, Sun D, Chen W, Yao X, et al. Intra-arterial tenecteplase for acute stroke after successful endovascular therapy: the ANGEL-TNK randomized clinical trial. JAMA 2025;334:582–591.
70. Hu W, Tao C, Wang L, Chen Z, Li D, Chen W, et al. Intra-arterial tenecteplase after successful endovascular recanalisation in patients with acute posterior circulation arterial occlusion (ATTENTION-IA): multicentre randomised controlled trial. BMJ 2025;388e080489.
71. Aladawi M, Abuawwad MT, Taha MJJ, Kozaa YA, Alrubasy WA, Hamad A, et al. Tenecteplase beyond 4.5 hours in acute ischemic stroke: a systematic review and meta-analysis of randomized clinical trials. J Stroke 2025;27:184–194.
72. Wang L, Dai YJ, Cui Y, Zhang H, Jiang CH, Duan YJ, et al. Intravenous tenecteplase for acute ischemic stroke within 4.5-24 hours of onset (ROSE-TNK): a phase 2, randomized, multicenter study. J Stroke 2023;25:371–377.
73. Cheng X, Hong L, Lin L, Churilov L, Ling Y, Yang N, et al. Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the CHABLIS-T II randomized clinical trial. Stroke 2025;56:344–354.
74. Xiong Y, Campbell BCV, Schwamm LH, Meng X, Jin A, Parsons MW, et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy. N Engl J Med 2024;391:203–212.
75. Ma G, Mo R, Zuo Y, Ma Q, Zhao G, Yao X, et al. Tenecteplase for acute non-large vessel occlusion 4.5 to 24 hours after ischemic stroke: the OPTION randomized clinical trial. JAMA 2026;335:1137–1147.
76. Albers GW, Jumaa M, Purdon B, Zaidi SF, Streib C, Shuaib A, et al. Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection. N Engl J Med 2024;390:701–711.
77. Xiong Y, Che F, Wang H, Hao M, Nguyen TN, Fisher M, et al. Intravenous tenecteplase prior to endovascular treatment for ischemic stroke at 4.5 to 24 hours: the TNK-PLUS randomized clinical trial. JAMA 2026;335:1849–1858.

Article information Continued

Figure 1.

Structural modifications of tenecteplase and their pharmacologic and practical implications. The figure compares the domain structure of alteplase and tenecteplase, highlighting the three engineered substitutions in tenecteplase (T103N, N117Q, and KHRR296-299AAAA). These modifications are associated with increased fibrin specificity, greater resistance to PAI-1, prolonged plasma half-life, and reduced systemic fibrinolysis. The lower panel also illustrates the difference in stroke dosing and administration, with alteplase requiring bolus plus 60-minute infusion and tenecteplase given as a single bolus. EGF, epidermal growth factor; TNK, tenecteplase; PAI-1, plasminogen activator inhibitor-1.

Table 1.

Key preclinical animal studies of tenecteplase in thrombosis and ischemic stroke models

Study Year Model/species Comparator Main finding Translational implication
Keyt et al. [14] 1994 Rabbit model Wild-type tPA (alteplase) Reduced clearance, preserved fibrinolytic activity, enhanced fibrin selectivity, and PAI-1 resistance Established the molecular basis for bolus thrombolysis
Benedict et al. [28] 1995 Rabbit arterial occlusion model Wild-type tPA (alteplase) Faster arterial recanalization without excess systemic bleeding Suggested that favorable PK/PD properties contributed to effective reperfusion
Chapman et al. [29] 2001 Rabbit embolic stroke model Wild-type tPA (alteplase) Comparable recanalization with a numerically lower hemorrhage burden Suggested an improved efficacy– safety profile in embolic stroke models
Lapchak et al. [15] 2004 Rabbit small-clot embolic stroke model Alteplase Improved thrombolytic and behavioral outcomes in embolic stroke Extended preclinical support for TNK in small embolic models
Correa-Paz et al. [30] 2024 Multicenter mouse embolic stroke model Alteplase Similar infarct reduction with less neuronal toxicity and early hemorrhagic transformation Provided contemporary multicenter validation of TNK efficacy

tPA, tissue-type plasminogen activator; PAI-1, plasminogen activator inhibitor-1; PK/PD, pharmacokinetics/pharmacodynamics; TNK, tenecteplase.

Table 2.

Dose exploration studies of tenecteplase

Trial Year Design/phase TNK dose(s) Comparator Population Main finding
Haley et al. [39] 2005 Pilot dose-escalation safety study 0.1, 0.2, 0.4, 0.5 mg/kg - AIS within 3 hours Reported that 0.1–0.4 mg/kg appeared safe enough for further study
TNK-S2B [40] 2010 Multicenter, randomized, phase IIb/III 0.1, 0.25, 0.4 mg/kg Alteplase 0.9 mg/kg AIS within 3 hours Early termination limited definitive conclusions, but the design and observed signals did not favor 0.4 mg/kg as the leading candidate
TAAIS [41] 2012 Multicenter, randomized, phase Iib 0.1 and 0.25 mg/kg Alteplase 0.9 mg/kg Perfusion-selected AIS with vessel occlusion, treated within 6 hours The higher dose of TNK (0.25 mg/kg) was superior to the lower dose and to alteplase for all efficacy outcomes, including absence of serious disability
ATTEST [43] 2015 Single center, randomized, phase II 0.25 mg/kg Alteplase 0.9 mg/kg AIS within 4.5 hours No significant difference in penumbral salvage, clinical outcome, or safety between groups
TEMPO-1 [44] 2015 Multicenter, nonrandomized study 0.1 and 0.25 mg/kg - Minor stroke (NIHSS ≤5) with proven intracranial occlusion TNK was feasible and safe; more favorable recanalization/outcome trends with 0.25 mg/kg
TRACE [42] 2022 Multicenter, randomized, phase II 0.1, 0.25, 0.32 mg/kg Alteplase 0.9 mg/kg AIS within 3 hours Suggested that 0.25 mg/kg provided the most encouraging numerical efficacy-safety balance, although no significant between-group differences were observed
TASTE-A [45] 2022 Multicenter, randomized, phase II 0.25 mg/kg Alteplase 0.9 mg/kg AIS within 4.5 hours (mobile stroke unit) Treatment with TNK on the mobile stroke unit resulted in a superior rate of early reperfusion compared with alteplase, and no safety concerns were noted
CHABLIS-T [46] 2024 Multicenter, randomized, phase Iia 0.25 and 0.32 mg/kg - AIS with salvageable brain tissue on perfusion imaging and presented within 4.5–24 hours Both 0.25 mg/kg and 0.32 mg/kg demonstrated sufficient promise of efficacy and safety

TNK, tenecteplase; TNK-S2B, Phase 2B Study of Tenecteplase in Acute Ischemic Stroke; TAAIS, Tenecteplase versus Alteplase for Acute Ischemic Stroke; ATTEST, Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis; TEMPO-1, TNK-Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke With Proven Occlusion; TRACE, Tenecteplase Reperfusion therapy in Acute ischemic Cerebrovascular Events; TASTE-A, Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance; CHABLIS-T, Chinese Acute Tissue-Based Imaging Selection for Lysis in Stroke-Tenecteplase; AIS, acute ischemic stroke; NIHSS, National Institutes of Health Stroke Scale.

Table 3.

Transitional phase II-III trials that established 0.25 mg/kg as the preferred tenecteplase dose in acute ischemic stroke

Trial Year Design/phase Comparison Population Main finding
EXTEND-IA TNK Part 1 [21] 2018 Multicenter, randomized, phase II TNK 0.25 mg/kg vs. alteplase 0.9 mg/kg LVO stroke eligible for thrombectomy within 4.5 hours TNK 0.25 mg/kg improved pre-thrombectomy reperfusion and was associated with better functional outcome than alteplase
EXTEND-IA TNK Part 2 [49] 2020 Multicenter, randomized, phase II TNK 0.25 mg/kg vs. TNK 0.4 mg/kg LVO stroke eligible for thrombectomy within 4.5 hours Dose escalation to 0.4 mg/kg did not improve reperfusion before thrombectomy; no efficacy advantage was demonstrated
NOR-TEST [50] 2017 Multicenter, randomized, phase III TNK 0.4 mg/kg vs. alteplase 0.9 mg/kg Broad range of AIS within 4.5 hours Overall efficacy and safety appeared similar
NOR-TEST 2A [51] 2022 Multicenter, randomized, phase III TNK 0.4 mg/kg vs. alteplase 0.9 mg/kg Moderate-to-severe AIS (NIHSS ≥6) within 4.5 hours Trial was stopped early; 0.4 mg/kg was associated with worse safety and functional outcomes than alteplase

EXTEND-IA TNK, Extending the time for Thrombolysis in Emergency Neurological Deficits-Intra-Arterial using intravenous Tenecteplase; NOR-TEST, Norwegian Tenecteplase Stroke Trial; TNK, tenecteplase; LVO, large-vessel occlusion; AIS, acute ischemic stroke; NIHSS, National Institutes of Health Stroke Scale.

Table 4.

Characteristics and outcomes of phase III non-inferiority trials comparing tenecteplase 0.25 mg/kg with alteplase in acute ischemic stroke

Trial Year/region Design/phase Sample size Median baseline NIHSS (IQR) Imaging selection criterion Population EVT policy Comparison Primary endpoint Main finding*
AcT [55] 2022/Canada Multicenter, registry-linked, randomized, phase III Total: 1,577 TNK: 9 (6–16) No advanced imaging selection required AIS within 4.5 hours EVT eligibility was not a selection criterion TNK 0.25 mg/kg vs. alteplase 0.9 mg/kg mRS 0–1 at 90–120 days 36.9% vs. 34.8%; non-inferiority met; sICH 3.4% vs. 3.2%
TNK: 806 Alteplase: 10 (6–17)
Alteplase: 771
TRACE-2 [57] 2023/China Multicenter, randomized, phase III Total: 1,417 TNK: 7 (5–10) No advanced imaging selection required AIS within 4.5 hours Patients ineligible for or refusing EVT TNK 0.25 mg/kg vs. alteplase 0.9 mg/kg mRS 0–1 at 90 days 62% vs. 58%; non-inferiority met; sICH 2% vs. 2%
TNK: 710 Alteplase: 7 (6–10)
Alteplase: 707
ATTEST-2 [58] 2024/UK Multicenter, randomized, phase III Total: 1,777 TNK: 7 (5–13) No advanced imaging selection required AIS within 4.5 hours EVT eligibility was not a selection criterion TNK 0.25 mg/kg vs. alteplase 0.9 mg/kg Distribution of 90-day mRS OR, 1.07 (95% CI 0.90–1.27), non-inferiority met; sICH 2% vs. 2%
TNK: 885 Alteplase: 7 (5–12)
Alteplase: 892
ORIGINAL [59] 2024/China Multicenter, randomized, phase III Total: 1,465 TNK: 6 (5–8.5) No advanced imaging selection required AIS within 4.5 hours EVT eligibility was not a selection criterion TNK 0.25 mg/kg vs. alteplase 0.9 mg/kg mRS 0–1 at 90 days 72.7% vs. 70.3%; non-inferiority met; sICH 1.2% vs. 1.2%
TNK: 732 Alteplase: 6 (5–9)
Alteplase: 733
TASTE [60] 2024/International, 8 countries Multicenter, randomized, phase III Total: 680 TNK: 7 (4–11) Salvageable tissue on CT or MR perfusion imaging AIS within 4.5 hours Generally focused on patients not proceeding to EVT in the trial framework TNK 0.25 mg/kg vs. alteplase 0.9 mg/kg mRS 0–1 at 90 days 57% vs. 55%; did not meet prespecified non-inferiority in the ITT population; per-protocol analysis supported non-inferiority; sICH 3% vs. 2%
TNK: 339 Alteplase: 7 (5–10)
Alteplase: 341
 

NIHSS, National Institutes of Health Stroke Scale; IQR, interquartile range; EVT, endovascular thrombectomy; AcT, Alteplase Compared with Tenecteplase; TRACE, Tenecteplase Reperfusion therapy in Acute ischemic Cerebrovascular Events; ATTEST, Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis; ORIGINAL, Optimal Reperfusion Strategy in Acute Ischemic Stroke with Low-Dose Tenecteplase; TASTE, Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation; TNK, tenecteplase; AIS, acute ischemic stroke; mRS, modified Rankin Scale; sICH, symptomatic intracranial hemorrhage; OR, odds ratio; CI, confidence interval; CT, computed tomography; MR, magnetic resonance; ITT, intention-to-treat.

*

The definition of sICH varied across trials and followed the prespecified criteria used in each original study.

Table 5.

Characteristics and outcomes of randomized trials of intravenous tenecteplase in the extended time window

Trial Year/region Design/phase Sample size Population EVT policy Comparison Primary endpoint Main finding
ROSE-TNK [72] 2023/China Multicenter, randomized, phase II 80 AIS, 4.5–24 hours Preplanned EVT excluded TNK 0.25 mg/kg vs. standard care mRS 0–1 at 90 days No significant difference in mRS 0–1 (52.5% vs. 50.0%; OR, 1.11; P=0.82)
CHABLIS-T II [73] 2025/China Multicenter, randomized, phase IIb 224 AIS with LVO or MeVO, 4.5–24 hours EVT permitted; (54.9% performed) TNK 0.25 mg/kg vs. standard care Major reperfusion without sICH* at 24–48 hours TNK increased major reperfusion without sICH*, but definitive 90-day functional benefit was not demonstrated
TRACE-III [74] 2024/China Multicenter, randomized, phase III 516 AIS with LVO, 4.5–24 hours Preplanned EVT excluded TNK 0.25 mg/kg vs. standard care mRS 0–1 at 90 days TNK increased mRS 0–1 (33.0% vs. 24.2%; RR, 1.37; P=0.03)
OPTION [75] 2026/China Multicenter, randomized, phase III 566 Non-LVO AIS, 4.5–24 hours Preplanned EVT excluded TNK 0.25 mg/kg vs. standard care mRS 0–1 at 90 days TNK increased mRS 0–1 (43.6% vs. 34.2%; RR, 1.28; P=0.02), with higher sICH*
TIMELESS [76] 2024/USA and Canada Multicenter, randomized, double blind, phase III 458 AIS with LVO, 4.5–24 hours EVT permitted; (77.3% performed) TNK 0.25 mg/kg vs. placebo Distribution of 90-day mRS No significant improvement in functional outcome (OR, 1.13; 95% CI 0.82–1.57; P=0.45)
TNK-PLUS [77] 2026/China Multicenter, randomized, phase III 391 AIS with Proximal MCA occlusion, 4.5–24 hours Preplanned EVT only TNK 0.25 mg/kg + EVT vs. EVT alone mRS 0–2 at 90 days No significant improvement in functional independence (44.2% vs. 43.2%; RR, 1.01; P=0.89)

EVT, endovascular thrombectomy; ROSE-TNK, MRI-guided thrOmbolysis for Stroke bEyond Time Window by Tenecteplase; CHABLIS-T, Chinese Acute Tissue-Based Imaging Selection for Lysis in Stroke-Tenecteplase; TRACE, Tenecteplase Reperfusion therapy in Acute ischemic Cerebrovascular Events; OPTION, Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke; TIMELESS, Thrombolysis in Imaging-Eligible, Late-Window Patients to Assess the Efficacy and Safety of Tenecteplase; TNK-PLUS, Endovascular Treatment With or Without Preceding Intravenous Tenecteplase in Patients With Late-Window Acute Ischemic Stroke Due to Middle Cerebral Artery Occlusion; AIS, acute ischemic stroke; TNK, tenecteplase; mRS, modified Rankin Scale; OR, odds ratio; LVO, large-vessel occlusion; MeVO, medium-vessel occlusion; sICH, symptomatic intracranial hemorrhage; RR, risk ratio; CI, confidence interval; MCA, middle cerebral artery.

*

The definition of sICH varied across trials and followed the prespecified criteria used in each original study.